- Home
- TPB vs JANX Comparison
TPB vs JANX Comparison
Compare TPB & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPB | JANX |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TPB | JANX |
|---|---|---|
| Price | $116.90 | $15.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $115.00 | $57.36 |
| AVG Volume (30 Days) | 352.6K | ★ 1.6M |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $435,716,000.00 | $10,000,000.00 |
| Revenue This Year | $29.51 | N/A |
| Revenue Next Year | $11.08 | N/A |
| P/E Ratio | $596.64 | ★ N/A |
| Revenue Growth | ★ 51.72 | N/A |
| 52 Week Low | $51.48 | $12.80 |
| 52 Week High | $119.25 | $47.58 |
Technical Indicators
Market Signals| Indicator | TPB | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 65.14 | 49.46 |
| Support Level | $114.31 | $12.80 |
| Resistance Level | $119.25 | $14.34 |
| Average True Range (ATR) | 4.08 | 0.59 |
| MACD | 0.75 | 0.45 |
| Stochastic Oscillator | 84.73 | 95.44 |
Price Performance
Historical ComparisonAbout TPB Turning Point Brands Inc.
Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.